Karyopharm Therapeutics Inc. 8-K

What Happened

• On May 14, 2026, Karyopharm Therapeutics Inc. announced its financial results for the quarter ended March 31, 2026 and said it will hold a previously announced, publicly available conference call to discuss those quarterly results and other company updates. The full press release is furnished as Exhibit 99.1 to the Form 8-K.

Key Details

• Filing date: May 14, 2026.
• Reporting period: quarter ended March 31, 2026.
• Press release containing the results is included as Exhibit 99.1 to the 8-K.
• The disclosure states the Form 8-K (including Exhibit 99.1) is not being “filed” under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless explicitly stated.

Why It Matters

• This 8-K signals that Karyopharm has published its quarterly earnings and will provide more detail during a public conference call — key opportunities for investors to hear management commentary on quarterly results, revenue and other financial metrics. Because the press release is furnished (not “filed”), investors should review Exhibit 99.1 and listen to the call for the specific revenue, earnings and operational details needed to assess near-term performance and guidance.